VDAC1 and breast carcinoma: We have demonstrated that silencing VDAC1 expression in tumors by 2′-O-Methyl-modified siRNA specific to human (h)VDAC1 (si-hVDAC1-2A) reduced cellular ATP levels and cell proliferation, and inhibited solid tumor development and growth in glioblastoma, cervical, lung and breast cancers [41,45,46,47,48,49,50,51].